Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Patent
1995-06-07
1997-06-10
Azpuru, Carlos
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
424423, 424427, 424430, 424434, 424435, 424436, 424437, 424451, 424464, 514275, A61F 202, A61F 902, A61L 1516, A61K 31505
Patent
active
056373147
ABSTRACT:
A method for treating atopic dermatitis, hayfever, asthma and pruritis that includes topical or systemic application of an effective amount of buspirone or a buspirone derivative or its pharmaceutically acceptable salt, other than a quaternary salt, optionally in a pharmaceutically-acceptable diluent or carrier.
REFERENCES:
patent: 3717634 (1973-02-01), Wu et al..
patent: 3976776 (1976-08-01), Wu et al.
patent: 4182763 (1980-01-01), Casten et al.
patent: 4351939 (1982-09-01), Simms et al.
patent: 4417049 (1983-11-01), Sims
patent: 4438119 (1984-03-01), Allen et al.
patent: 4468391 (1984-08-01), Voith
patent: 4515947 (1985-05-01), Sandefur et al.
patent: 4620006 (1986-10-01), Sandefur et al.
patent: 4634703 (1987-01-01), Kurtz et al.
patent: 4636563 (1987-01-01), Abou-Gharbia
patent: 4640921 (1987-02-01), Othmer et al.
patent: 4687772 (1987-08-01), Alderdice
patent: 4696927 (1987-09-01), Gittos et al.
patent: 4709027 (1987-11-01), Abou-Gharbia et al.
patent: 4732984 (1988-03-01), Abou-Gharbia et al.
patent: 4748240 (1988-05-01), Stack et al.
patent: 4777173 (1988-10-01), Shrotryia et al.
patent: 4788189 (1988-11-01), Glazer
patent: 4810789 (1989-03-01), Behme et al.
patent: 4812567 (1989-03-01), Abou-Gharbia
patent: 4851533 (1989-07-01), Abou-Gharbia
patent: 4883875 (1989-11-01), Abou-Gharbia
patent: 4895848 (1990-01-01), Traber et al.
patent: 4900835 (1990-02-01), Abou-Gharbia
patent: 4927934 (1990-05-01), Abou-Gharbia et al.
patent: 4940585 (1990-07-01), Hapworth et al.
patent: 4943428 (1990-07-01), Lucot et al.
patent: 4963557 (1990-10-01), Badger et al.
patent: 5015646 (1991-05-01), Simms
patent: 5032578 (1991-07-01), Horovitz
patent: 5053508 (1991-10-01), Schiehser et al.
patent: 5096908 (1992-03-01), Gidda et al.
patent: 5098889 (1992-03-01), Costall et al.
patent: 5114947 (1992-05-01), Imondi
patent: 5134140 (1992-07-01), Stack
patent: 5162322 (1992-11-01), Taylor, Jr. et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169638 (1992-12-01), Dennis et al.
patent: 5183819 (1993-02-01), Abou-Gharbia et al.
patent: 5185329 (1993-02-01), Gawin et al.
patent: 5187277 (1993-02-01), Komissarov et al.
patent: 5244902 (1993-09-01), Sharpe et al.
patent: 5256408 (1993-10-01), Babcock et al.
patent: 5290783 (1994-03-01), Sharpe et al.
patent: 5484788 (1996-01-01), Sharpe et al.
Allen, L.E., et al., "Pharmacologic Effects of MJ 9022-1, a Potential tranquilizing Agent," Arneimittel-Forsch, 24:917 (1974)*.
Ameisen, J.C., et al., "A New Interpretation of the Involvement of Serotonin in Delayed-Type Hypersensitivity," J. Immunology, 142:(9):3171-3179 (1989)*.
Arndt, K.A., et al., "The Pharmocology of Topical Therapy," Dermatology in General Medicine, Ch. 211, 2532-40, T.B. Fitzpatrick, A.Z. Eisen, K. Wolff, I.M., Freedberg and K.F. Austen, eds., 3d ed., McGraw Hill, Inc., New YOrk (1987)*.
Backerman, "Premenstrual syndrome Update--1991," Md. Med. J. 40:1003-1009 (1991).
Balster, et al., "IntravenousBuspirone Self-Administration in Rhesus Monkeys," J. Clin. Psychiatry, 43:34-39 (1982).
Barbee, et al., "A Comparison of the Single-Dose Effects of Alprazolam, Buspirone, and Placebo Upon Memory Function," J. Clin. Psychopharmacol., 11:351-356 (1991).
Blozovski and Sivadjian, "The Action of Serotonin, Reserpine and Other Pharmacological Agents on Sudoral Secretion", Chemical Abstracts, 54:21504 (1960)*.
Bohn and Gammans, "Buspirone Therapy for Elderly Patients with Anxiety or Depressive Neurosis," J. Clin. Psychiatry, 51:309 (1990).
Bowden, et al., "New Developments in the Treatment of Anxiety Disorders," Texas Medicine, 84:38-42 (1988).
Bruning, et al., "Quantitative Autoradiographic Distribution and Pharmacological Characterization of (3H) Buspirone Binding to Sections from Rat, Bovine and Marmoset Brain," J. Neural Transm, 78:131-144 (1989).
Bruno, "Buspirone in the Treatment of Alcoholic Patients," Psychopathology, 1:49-59 (1989).
Budhram, et al., "Some Putative Non-Sedating Anxiolytics in a Bonditioned Licking Conflict," Brit. J. Pharmacol., 88:331P (1986).
Caccia, S., et al., "Disposition and Metabolism of Buspirone and its Metabolite 1-(2-Pyrimidinyl)-piperazine in the Rat," Xenobiotica, 13(3):147-153 (1983)*.
Caccia, et al., "Identification and Quantitation of 1-(2-pyrimidinyl)piperazine, an Active Metabolite of the Anxiolytic Agent Buspirone, in Rat Plasma and Brain," J. Chromatogr., 252:310-314 (1982).
Caccia, et al., "Disposition of the Psychotropic Drugs Buspirone, MJ-13805 and Piribedil, and of Their Common Active Metabolite 1-(2-Pyrimindinyl)-Piperazine in the Rat," Xenobiotica, 15:835-844 (1985).
Caccia, et al., "1-(2-Pyrimidinyl)-Piperazine as Active Metabolite of Buspirone in Man and Rat," Pharmacology, 33:46-51 (1986).
Carli, et al., "Effect of 5-HT.sub.1A Agonists on Stress-Induced Deficit in Open Field Locomotor Activity of Rats: Evidence That This Model Identifies Anxiolytic-Like Activity," Neuropharacology, 285:471-476 (1989).
Cimino, et al., "Dopaminergic Effects of Buspirone, a Novel Anxiolytic Agent," Biochem. Pharmacol., 32:1069-1074 (1983).
Coffman, J.D., "The Attenuation by Reserpine or Guanethidine of the Cutaneous Vasoconstriction caused by Tobacco smoking," Amer. Heart J., vol. 74, No. 2, pp. 229-234 (1967).
Cohn, et al., "Low-Sedation Potential of Buspirone Compared with Alprazolam and Lorazepam in the Treatment of Anxious Patients: a Double-Blind Study," J. Clin. Psychiatry, 47:409-412 (1986).
Dommisee, et al., "Formulating Forum Buspirone: a New Type of Anxiolytic," Drug Intell. Clin. Pharm., 19:624-627 (1985).
Dostal, G. and Gamelli, R.L., "The Differential Effect of Corticosteroids on Wound Disruption Strength in Mice," Arch. Surg., vol. 125, pp. 636-640 (1990)*.
Eison, A.S., Temple, D.L. "Buspirone: Review of its Pharmacology and Current Perspectives on its Mechanism of Action," Am. J. Med., 80(Supp. 3B):1-9 (1986)*.
Feighner, "Buspirone in the Long-Term Treatment of Generalized Anxiety Disorder," J. Clin. Psychiatry, 48:3-6 (1987).
Fishel, R., et al., "Cyclosporin A Impairs Wound Healing In Rats," J. Surg. Research, 34:572-575 (1983)*.
Freire-Garabal, et al., "Effects of Buspirone on the Immunosuppressive Response to Stress in Mice," Arch. Int. Pharmacodyn Ther., 314:160-168 (1991)*.
Galli and Hammel, "Unequivocal Delayed Hypersensitivity in Mast Cell-Deficient and BeigeMice", Science, 226:710-13 (1984)*.
Gammans, et al., "Buspirone Disposition in Rhesus Monkeys," Fed. Proc., Drug Disposition, 2316:634 (1981).
Gammans, et al., "Concentration of Buspirone and 1-Pyrimidinylpiperazine, a Metabolite, in Rat Brain," Fed. Proc., Metabolism and Disposition: Absorption, Distribution, and Excretion, 495:377 (1983).
Gammans, "The Effects of Buspirone Binding of Digoxin, Dilantin, Propanolol and Warfarin to Human Plasma," Fed. Proc., Drug Binding, 4165:1123 (1985).
Gammans, et al., "Metabolism and Disposition of Buspirone," Am. J. Med., 80 (Supp. B):41-51 (1986).
Gammans, et al., "Pharmacokinetics of Buspirone in Elderly Subjects," J. Clin. Pharmacol., 29:72-78 (1989).
Garrattini, et al., "Notes on Buspirone's Mechanisms of Action," J. Clin. Psychiatry, 43:19-24 (1982).
Geller and Hartmann, "Effects of Buspirone on Operant Behavior of Laboratory Rats and Cynomolgus Monkeys," J. Clin. Psychiatry, 43:25-33 (1982).
Glaser and Traber, "Buspirone Action on Serotinin Receptors in Calf Hippocampus," Eur. J. Pharmacol., 88:137-138 (1983).
Goa, K.L. and Ward, A., "Buspirone: A Preliminary Review of its Pharmacological Properties and Therapeutic Efficacy as an Anxiolytic," Drugs, vol. 32, pp. 114-129 (1986)*.
Goldberg, "Buspirone Hydrochloride: a Unique new Anxiolytic Agent. Pharmacokinetics, Clinical Pharmacology, Abuse Potential and Clinical Efficacy," Pharmacotherapy, 4:315-324 (1984).
Goldberg, L., and Finnerty, R., "Comparative Efficacy of Buspirone and Diazepam in the Treatment of Anxiety," Am. J. Psychiatry, vol. 136, No. 9, pp. 1184-1187 (1979)*.
Gozlan, et al., "Identification of Presynaptic Serotinin Autoreceptors Using a New Ligand: .sup.3 H-PAT," Nature (London),
Griffith, et al., "Investigation of the Abuse Liability of Buspirone in Alcohol-Dependent Patien
Arndt Kenneth A.
Galli Stephen J.
Sharpe Richard J.
Azpuru Carlos
Beth Israel Deaconess Medical Center Inc.
LandOfFree
Topical and systemic application of buspirone or derivatives the does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical and systemic application of buspirone or derivatives the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical and systemic application of buspirone or derivatives the will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-763023